Clinical Trial News and Research

RSS

GenPath, BioReference Labs to introduce OnkoMatch solid tumor genotype test

BioReference Laboratories, Inc. and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts General Hospital (MGH) is introducing its groundbreaking solid tumor genotype test.

27 Jan 2012

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

27 Jan 2012

Amorcyte commences enrollment in PreSERVE Phase 2 trial for acute myocardial infarction

Amorcyte, LLC, a NeoStem, Inc. company today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.

25 Jan 2012

St. Jude Medical fourth quarter net sales increase 4% to $1.407B

St. Jude Medical, Inc. today reported sales and net earnings for the fourth quarter and year ended December 31, 2011.

25 Jan 2012

UH Case Medical Center initiates enrollment in Moxy Drug Coated Balloon trial for PAD

Physicians at University Hospitals (UH) Case Medical Center enrolled their first patient in LEVANT 2, a global, multicenter, randomized clinical trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon for the treatment of peripheral arterial disease.

25 Jan 2012

Cohera receives FDA IDE approval to initiate U.S. clinical study for TissuGlu

Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration ("FDA") to begin a prospective, multicenter, randomized clinical trial for its lead product, TissuGlu Surgical Adhesive in the United States.

25 Jan 2012

Enrollment complete in Medtronic's CoreValve U.S. Trial for severe aortic stenosis

Medtronic, Inc. today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation to continue enrolling extreme risk patients under a Continued Access Study protocol.

From Medtronic 25 Jan 2012

Cytori's ADRCs safe and feasible for patients with AMI

Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.

25 Jan 2012

IHS experts develop new guidelines for migraine clinical trials

Experts from the International Headache Society (IHS) have developed new recommendations for conduct of acute and preventive migraine clinical trials. The third edition of Migraine Clinical Trials Guidelines is now available in the IHS journal Cephalalgia, which is published by SAGE.

25 Jan 2012

Gilead commences GS-7340 Phase 2 trial in HIV

Gilead Sciences, Inc. today announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

Dutasteride delays prostate cancer progression in men

For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network.

24 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

23 Jan 2012

Haymarket Media launches ChemotherapyAdvisor.com

Haymarket Media Inc., publisher of Monthly Prescribing Reference (MPR), MPR Hematology/Oncology Edition, and Oncology Nurse Advisor (ONA), is pleased to announce the launch of ChemotherapyAdvisor.com, offering oncologists and their support teams a unique clinical decision support tool.

23 Jan 2012

Chronic inflammation combines with DNA methylation to promote development of colorectal cancer

Chronic inflammation combines with DNA methylation, a process that shuts down cancer-fighting genes, to promote development of colorectal cancer, scientists at The University of Texas MD Anderson Cancer Center report today in the advance online publication of the journal Nature Medicine.

23 Jan 2012

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.

20 Jan 2012

ARCA biopharma receives method patent for treatment with bucindolol based on genetic targeting

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype - homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor.

20 Jan 2012

ArmAssist project to find out degree of satisfaction in patients with brain stroke

Today 15 million persons throughout the world suffer from an ictus every year and 5 million are left with chronic disabilities. TECNALIA designed a system for alleviating neuromuscular disability amongst these patients from their homes and by which these can be permanently supervised by the therapist who will be able to carry out a quantitative evaluation of the therapy. To this end, they have brought together new technologies and entertainment and a greater quality of rehabilitation.

20 Jan 2012

Clues about how statins might treat breast cancer

Cholesterol-lowering statins seem to keep breast cancer at bay in some patients. Now researchers reporting in the January 20th issue of the journal Cell, a Cell Press publication, provide clues about how statins might yield those unexpected benefits. The findings also suggest that mutations in a single gene could be used to identify tumors likely to respond to statin therapy.

19 Jan 2012

Clinical Trial News and Research

GenPath, BioReference Labs to introduce OnkoMatch solid tumor genotype test

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Amorcyte commences enrollment in PreSERVE Phase 2 trial for acute myocardial infarction

St. Jude Medical fourth quarter net sales increase 4% to $1.407B

UH Case Medical Center initiates enrollment in Moxy Drug Coated Balloon trial for PAD

Cohera receives FDA IDE approval to initiate U.S. clinical study for TissuGlu

Enrollment complete in Medtronic's CoreValve U.S. Trial for severe aortic stenosis

Cytori's ADRCs safe and feasible for patients with AMI

IHS experts develop new guidelines for migraine clinical trials

Gilead commences GS-7340 Phase 2 trial in HIV

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

Dutasteride delays prostate cancer progression in men

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Haymarket Media launches ChemotherapyAdvisor.com

Chronic inflammation combines with DNA methylation to promote development of colorectal cancer

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

ARCA biopharma receives method patent for treatment with bucindolol based on genetic targeting

ArmAssist project to find out degree of satisfaction in patients with brain stroke

Clues about how statins might treat breast cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer